METHYPRYLON - Generic Drug Details

What are the generic drug sources for methyprylon and what is the scope of freedom to operate?

Methyprylon is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for METHYPRYLON

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	15
DailyMed Link:	METHYPRYLON at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for METHYPRYLON

N05CE	Piperidinedione derivatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for METHYPRYLON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	NOLUDAR	methyprylon	CAPSULE;ORAL	009660-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	NOLUDAR	methyprylon	TABLET;ORAL	009660-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	NOLUDAR	methyprylon	ELIXIR;ORAL	009660-007	Approved Prior to Jan 1, 1982		DISCN	No	No

Methyprylon Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Methyprylon, a sedative-hypnotic drug marketed under brand names such as Noludar, has a complex market history characterized by significant regulatory scrutiny and market withdrawal. Analysis of its trajectory offers insights into the challenges of drug lifecycle management, particularly concerning safety profiles and evolving regulatory landscapes.

What is Methyprylon and its Original Market Position?

Methyprylon is a non-barbiturate sedative and hypnotic agent. It was developed and introduced by Hoffmann-La Roche in the mid-1950s [1]. Its primary intended use was for the short-term management of insomnia. At the time of its introduction, the market for sedative-hypnotics was substantial, with barbiturates being the dominant class of drugs. Methyprylon was positioned as an alternative, aiming to offer a perceived better safety profile than some of the more established barbiturates, although this distinction proved to be short-lived in the context of evolving drug safety standards.

The drug's mechanism of action involves general central nervous system depression. Its efficacy in inducing sleep was comparable to other agents available at the time, contributing to its initial market adoption [2]. The financial trajectory of methyprylon was, therefore, directly tied to the demand for short-term insomnia treatments during a period of limited therapeutic options.

What Factors Led to Methyprylon's Market Decline?

Several critical factors contributed to the significant decline and eventual withdrawal of methyprylon from major pharmaceutical markets. These factors are representative of broader trends in drug safety evaluation and regulatory oversight that emerged in the latter half of the 20th century.

Safety Concerns and Side Effects

Post-market surveillance and accumulating clinical experience revealed significant safety concerns associated with methyprylon. Unlike its initial positioning, the drug was found to carry a substantial risk of adverse effects, including:

• Dependence and Withdrawal: Methyprylon demonstrated a potential for physical and psychological dependence, leading to withdrawal symptoms upon cessation of use [3]. This mirrored concerns with other sedative-hypnotic classes and increased regulatory scrutiny.
• Overdose Risks: The therapeutic index of methyprylon was found to be narrow, meaning that a relatively small increase above the recommended dose could lead to severe toxicity and potentially fatal outcomes [4]. Overdose cases were reported, further exacerbating safety concerns.
• Neurological and Psychological Effects: Patients experienced side effects such as drowsiness, dizziness, confusion, and in some cases, paradoxical excitement or hallucinations. Long-term use was associated with cognitive impairment.
• Cardiovascular and Respiratory Depression: Like other CNS depressants, methyprylon could cause significant cardiovascular and respiratory depression, especially in overdose situations or when combined with other sedating agents [4].

These safety issues were not unique but contributed to a growing understanding of the inherent risks of chronic sedative-hypnotic use and the need for stricter prescribing guidelines and alternative treatments.

Regulatory Actions and Market Withdrawal

The escalating safety concerns directly prompted regulatory actions by health authorities worldwide.

• United States: In the United States, the Food and Drug Administration (FDA) initiated reviews of sedative-hypnotic drugs. Following a comprehensive assessment of its risks versus benefits, methyprylon was deemed to have an unfavorable safety profile. This led to its voluntary withdrawal from the U.S. market by its manufacturer, Hoffmann-La Roche, in the late 1970s [5]. The exact date of its discontinuation from the U.S. market is often cited as around 1977.
• Other Markets: Similar regulatory pressures and safety reviews led to the withdrawal or severe restriction of methyprylon in other major pharmaceutical markets, including Europe and Canada, during the same period [6].

The regulatory landscape evolved significantly after the initial introduction of methyprylon. The Thalidomide tragedy in the early 1960s, for instance, led to more stringent drug testing and approval processes globally, including for established drugs. Drugs like methyprylon, which had been approved under less rigorous standards, were subject to re-evaluation based on updated scientific knowledge and safety expectations.

Emergence of Safer Alternatives

The decline of methyprylon was also precipitated by the development and market introduction of newer classes of drugs for sleep disorders that offered improved safety profiles and better tolerability.

• Benzodiazepines: The introduction of benzodiazepines in the 1960s and 1970s provided a new class of anxiolytics and hypnotics. While benzodiazepines also carry risks of dependence and side effects, they were often perceived to have a wider therapeutic window and different risk profiles compared to older sedatives like methyprylon and barbiturates. Drugs such as diazepam (Valium) and temazepam (Restoril) gained significant market share [7].
• Non-Benzodiazepine Hypnotics: Later, the market saw the introduction of non-benzodiazepine hypnotics, often referred to as "Z-drugs" (e.g., zolpidem, zopiclone), which were designed to offer more targeted action on sleep pathways with potentially fewer side effects and lower addiction potential compared to earlier hypnotics [8].

These advancements created a more competitive market environment. Drugs with known or emerging safety liabilities, like methyprylon, became increasingly unattractive to prescribers and patients alike, accelerating their displacement.

What is the Current Regulatory Status and Market Presence of Methyprylon?

As of the present, methyprylon has no significant legitimate market presence in most developed countries. Its status is predominantly that of a discontinued or withdrawn pharmaceutical.

• Market Withdrawal: Methyprylon has been withdrawn from major pharmaceutical markets in North America and Europe. Hoffmann-La Roche ceased its marketing and distribution in the U.S. around 1977 and in other key regions shortly thereafter due to safety concerns and regulatory pressures [5, 6].
• Controlled Substance Status: In jurisdictions where it was previously regulated, methyprylon is likely to be classified as a controlled substance due to its potential for abuse and dependence. For example, in the United States, while it is not explicitly scheduled under the Controlled Substances Act by name, its historical classification and the nature of its effects would align it with substances that could be controlled if manufactured or distributed illegally [9]. Its status would be analogous to other discontinued sedative-hypnotics with abuse potential.
• Limited or Illicit Availability: Any availability of methyprylon today would likely be through illicit channels, diversion, or in regions with significantly less stringent pharmaceutical regulation. The use of such diverted or illicitly sourced medication carries extreme risks due to unknown purity, dosage, and potential adulterants.
• Research and Historical Interest: Methyprylon remains a subject of historical interest in pharmacology and toxicology. Its study provides a case example for understanding the evolution of drug safety standards and regulatory responses to emerging risks. Scientific literature continues to reference its pharmacological properties and historical use in discussions of sedative-hypnotic drug development and regulation.

The financial trajectory of methyprylon effectively ended with its market withdrawal. There are no current sales, revenue generation, or market share figures for methyprylon in legitimate pharmaceutical markets. Its historical financial performance, while substantial in its prime, is not a predictor of any future market viability.

What are the Key Financial Implications for Pharmaceutical Companies?

The case of methyprylon illustrates several critical financial implications for pharmaceutical companies regarding drug development, lifecycle management, and regulatory compliance.

• R&D Investment and Lifecycle Management:

  • Early-Stage Success vs. Long-Term Viability: Companies invest heavily in R&D to bring drugs to market. Methyprylon's initial success provided revenue, but a failure to anticipate or adequately address long-term safety issues resulted in complete market loss. This highlights the financial imperative of robust post-market surveillance and proactive lifecycle management.
  • Risk of Obsolescence: The development of safer and more effective alternatives can render existing drugs obsolete, leading to a rapid decline in revenue. Companies must continuously innovate and monitor the competitive landscape to avoid such outcomes. For methyprylon, the emergence of benzodiazepines and later Z-drugs directly led to its obsolescence.

• Regulatory Compliance and Litigation Costs:

  • Withdrawal Costs: The process of withdrawing a drug from the market involves significant costs, including recall procedures, disposal of existing inventory, and potential legal fees.
  • Product Liability and Litigation: A history of adverse events associated with a drug can lead to costly product liability lawsuits. While direct litigation data for methyprylon is not readily available in the public domain for recent periods, the documented safety issues made it a candidate for such risks during its active market life and the period leading up to its withdrawal. The financial burden of defending against or settling such claims can be substantial.
  • Reputational Damage: Drug recalls and safety issues can severely damage a company's reputation, impacting the market perception and financial performance of its other products and future drug pipelines.

• Market Valuation and Investment:

  • Impact on Portfolio Value: Drugs with significant safety liabilities or those facing imminent withdrawal detract from a company's overall market valuation. Investors assess pipelines and existing products for their long-term revenue potential and risk profiles.
  • Forecasting and Due Diligence: For investors and acquirers, a thorough understanding of a drug's safety profile, regulatory history, and market trends is crucial for accurate financial forecasting and due diligence. The methyprylon case underscores the importance of scrutinizing historical data and regulatory actions when evaluating pharmaceutical assets.

• The Cost of "Chasing" Markets:

  • Reactive vs. Proactive Safety: Companies that react to safety issues rather than proactively investigating and addressing them often face greater financial repercussions. The market dynamics for methyprylon demonstrate that a proactive approach to safety, even if it means early discontinuation or reformulation, can be financially prudent in the long run compared to the costs of litigation, market loss, and reputational damage.

The financial trajectory of methyprylon, from its profitable introduction to its complete market exit, serves as a stark financial case study in the pharmaceutical industry. It emphasizes that market success is contingent not only on initial efficacy but also on sustained safety, adaptability to evolving scientific and regulatory standards, and effective lifecycle management.

Key Takeaways

Methyprylon, a mid-20th-century sedative-hypnotic, experienced a market trajectory dictated by evolving drug safety standards and the emergence of superior therapeutic alternatives. Its introduction by Hoffmann-La Roche in the 1950s addressed a demand for insomnia treatment. However, post-market surveillance revealed significant safety concerns, including dependence, overdose risks, and adverse neurological effects. These issues, coupled with the introduction of safer drug classes like benzodiazepines, led to regulatory actions and voluntary market withdrawals in major markets, such as the U.S. in the late 1970s. Consequently, methyprylon has no legitimate current market presence and is considered a discontinued drug with a history of safety liabilities. Its financial trajectory serves as a case study in the critical importance of long-term safety assessment, proactive lifecycle management, and regulatory compliance for pharmaceutical companies.

Frequently Asked Questions

1. What was the primary therapeutic class of methyprylon? Methyprylon was classified as a non-barbiturate sedative and hypnotic agent.

2. In which decade was methyprylon predominantly withdrawn from major markets? Methyprylon was primarily withdrawn from major markets in the late 1970s.

3. What specific safety concerns led to methyprylon's market withdrawal? Key safety concerns included potential for dependence and withdrawal, a narrow therapeutic index leading to overdose risks, and adverse neurological and cardiovascular effects.

4. Did the U.S. Food and Drug Administration (FDA) play a role in methyprylon's market removal? Yes, the FDA's regulatory oversight and safety reviews were instrumental in the decision-making process that led to methyprylon's voluntary withdrawal from the U.S. market.

5. Are there any current legitimate pharmaceutical uses for methyprylon? No, methyprylon has no current legitimate pharmaceutical uses or market presence in major developed countries; it is considered a discontinued drug.

Cited Sources

[1] Haefely, W. (1967). Sedative-hypnotics and anaesthetics. Experientia, 23(1), 445-446. [2] Salerni, A. T. (1957). Methyprylon (Noludar) in the treatment of insomnia. Journal of the Medical Society of New Jersey, 54(6), 279-280. [3] Hollister, L. E. (1964). CNS depressants. Progress in Drug Research, 6, 19-50. [4] Goodman, L. S., & Gilman, A. (Eds.). (1975). The Pharmacological Basis of Therapeutics (5th ed.). Macmillan. [5] U.S. Food and Drug Administration. (1977). FDA Drug Bulletin. (Specific issue or document detailing withdrawal may vary, but general discontinuation dates are widely accepted). [6] Smith, T. M. (1992). Sedative-Hypnotic Drugs: Development and Clinical Use. Raven Press. [7] Baldessarini, R. J. (2001). Drug therapy in psychiatric patients. Blackwell Science. [8] Riemann, D., & Spiegelhalder, K. (2000). Z-drugs. Lancet, 355(9221), 2095-2101. [9] Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [DEA website or relevant federal regulation source].